Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company’s decision to trim its 2025 financial outlook.
This marks the second time this year the company has revised its guidance downwards, signaling growing headwinds in key markets. Novo Nordisk now projects 2025 sales growth to be in the range of 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%.
